Author

Manish S. Patankar

University of Wisconsin–MadisonORCID 0000-0002-8205-6432Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 3 Approach:experimental assay· 3 Organism:human· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Organism:mouse· 1

Frequent Co-Authors

Lisa Marie BarroilhetiD· 2 shared Nicha BoonpattrawongiD· 2 shared Alexa R. HeatoniD· 1 shared Ana Sofia Peraza Munuzuri· 1 shared Andrea PennatiiD· 1 shared Aurora D’AmatoiD· 1 shared Catigan A. HedicaniD· 1 shared Ellinore K Letts· 1 shared

Activity by Year

2026-2026 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Lisa Marie BarroilhetORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Modeling the metabolic heterogeneity of high-grade serous ovarian cancer solid tumors in 3D Microphysiological systems

Paula M. Mañán-Mejías, Nicha Boonpattrawong, Michael Bérubé, Ellinore K Letts, Finnbar L. K. Reed-McBain, Ana Sofia Peraza Munuzuri, Yalmarie Numan Vazquez, Manish S. Patankar, Marı́a Virumbrales-Muñoz

This paper develops a 3D microphysiological system to model metabolic heterogeneity in HGSOC spheroids and tests the effect of atovaquone on tumor progression and metabolism.

bioRxiv · Jul 1, 2026 · PreprintCancer Biology

An autologous cell-based therapeutic vaccine expressing IL6/1 fusokine drives robust anti-tumor response against ovarian cancer.

Sejal Sharma, Rahul Das, Andrea Pennati, Catigan A. Hedican, Lisa Marie Barroilhet, Manish S. Patankar, Jacques Galipeau

This paper develops an IL6/1 fusokine that enhances T cell survival and anti-tumor response in a preclinical ovarian cancer model.

bioRxiv · May 8, 2026 · PreprintImmunology

Atovaquone-induced therapeutic rewiring of melanoma metabolism

Mayra A. Betancourt Ponce, Alexa R. Heaton, Samantha K. Burkard, Aurora D’Amato, Nicha Boonpattrawong, Melissa C. Skala, Manish S. Patankar, Lisa Marie Barroilhet

This study shows atovaquone inhibits OXPHOS and glycolysis in melanoma, causing metabolic reprogramming, oxidative stress, and reduced tumor growth in vitro and in vivo.

Journal of Investigative Dermatology · Mar 24, 2026Peer-reviewedCancer Biology